EE169 Novel Post-Processing Methods for Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Heat Map and Density-Based Clustering von Dziedzic, J., Pochopien, M., Clay, E.

Volltext

PRM80 Proportional Hazards Assumption and Its Impact on Results of Cost-Effectiveness Analysis von Pochopien, M, Zerda, I, Gwiosda, B, Plisko, R

Volltext

EE82 Economic Modelling of Gene Therapies Based on the Comparison of Two Independent Models Assessing Voretigene Neparvovec for RPE65 - Mediated Inherited Retinal Dystrophy von Janik, J, Paterak, E, Pochopien, M, Aballea, S, Toumi, M

Volltext

EE122 From Quality-Adjusted Life Years (QALY) to Equal Value of Life Years (evLY): A Study on Non-Alcoholic Steatohepatitis (NASH) Subpopulations von Zemojdzin, M, Pochopien, M, Dziedzic, J, Clay, E, Aballea, S, Toumi, M

Volltext

CO112 The Most Often Utilized Clinical Endpoints for Assessing Treatment Efficacy in Nonalcoholic Fatty Liver or Nonalcoholic Steatohepatitis von Polek, H, Pochopien, M, Dziedzic, J, Clay, E, Aballea, S, Toumi, M

Volltext

EE320 Impact of NASH Disease Model Adjustment to New Literature Findings: Assessing Cost-Effectiveness of Actual and Theoretical Treatments von Pochopien, M., Dziedzic, J., Clay, E., Aballea, S., Żerda, I., Toumi, M., Borissov, B.

Volltext

EE471 Investigating the Impact of Pseudo-Random Numbers Generator on a Probabilistic Sensitive Analysis (PSA) Results von Dziedzic, J., Pochopien, M., Aballea, S., Clay, E., Żerda, I., Toumi, M.

Volltext

CO158 Analysis of Clinical Endpoints in Clinical Trials for NAFL and NASH: A Comprehensive Review von Pochopien, M., Dziedzic, J., Aballea, S., Clay, E., Toumi, M., Borissov, B.

Volltext

EE271 Cost-Effectiveness of Finerenone in Addition to Standard-of-Care in Treating Type 2 Diabetes and Chronic Kidney Disease in China von He, Y., Ming, J., Chen, J., Hong, G., Xu, Y., Mernagh, P., Pochopien, M., Li, H.

Volltext

EE105 Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients With Haemophilia B Without Inhibitors von Pochopien, M, Tytuła, A, Toumi, M, Falk, A, Cioni, L, Hakimi, Z, Eriksson, D

Volltext

EE283 Cost-Effectiveness Analysis of Cell-Based Therapy for Patients with Non-Alcoholic Fatty Liver Disease von Aballea, S, Karwala, P, Zerda, I, Toumi, M, Pochopien, M, Han, R, Borissov, B, Clay, E

Volltext

EE179 Key Drivers of the Economically Justifiable Price of the COVID-19 Vaccine in England von Aballea, S, Karwala, P, Zerda, I, Toumi, M, Pochopien, M, Borissov, B, Clay, E

Volltext

RWD187 Patient Profiles and Treatment Patterns in Moderate-to-Severe Plaque Psoriasis in Poland von Owczarek, W., Walecka-Herniczek, I., Pochopien, M., Koziara, K., Łanecka, A., Górecki, M., Clay, E., Wojciechowski, P., Aballea, S., Toumi, M.

Volltext

CO150 Real-World Effectiveness of Biologic Agents Used to Treat Moderate-to-Severe Plaque Psoriasis in Poland: Between Treatment Comparison von Owczarek, W, Walecka-Herniczek, I., Pochopien, M, Koziara, K, Łanecka, A, Górecki, M, Wojciechowski, P, Clay, E, Aballea, S, Toumi, M

Volltext

PDB16 ASSESSMENT OF COST-EFFECTIVENESS OF A 0.2 ΜCG/DAY FLUOCINOLONE ACETONIDE (FAC) IMPLANT IN PATIENTS WITH CHRONIC DIABETIC MACULAR OEDEMA (DMO) IN AN EYE WITH CATARACT von Beiderbeck, A., Aballea, S., Pochopien, M., Bellier, L., Toumi, M.

Volltext

EE96 Cost-Effectiveness of Finerenone in Chronic Kidney Disease Associated With Type 2 Diabetes: Impact of Recent Guideline Implementation on Results of the FINE-CKD Model von Pochopien, M, Cherney, D, Folkerts, K, Levy, P, Millier, A, Morris, S, Chaudhry, PR, Sullivan, SD, Mernagh, P

Volltext

PRM44 - DIFFERENTIATING DISCOUNT RATES IN COST-EFFECTIVENESS EVALUATIONS IN THE CONTEXT OF GENE THERAPIES von Clay, E, Pochopien, M, Aballea, S, Toumi, M

Volltext

PRM123 - AN OVERVIEW OF OPEN-SOURCE MODELS IN HEALTH ECONOMICS von Michalczyk, J, Clay, E, Pochopien, M, Aballea, S

Volltext

PND32 Cost-Utility Analysis of Ropinirole in Parkinson'S Disease (PD) Treatment von Zerda, I, Drozdz, A, Brzyski, D, Pochopien, M, Gwiosda, B, Lisiecka, B, Barlog, D, Glogowski, C, Dziurda, D, Rys, P, Plisko, R

Volltext

PSS5 COMPARING TWO TREAT-AND-EXTEND ANTI-VEGF REGIMENS FOR MANAGING WET AGE-RELATED MACULAR DEGENERATION - IMPLICATIONS FOR THE NATIONAL HEALTH SYSTEM IN FRANCE von Pochopien, M., Palarcyzk, M., Clay, E., Koerber, C., Boitte, M., Deschaseaux, C., Toumi, M.

Volltext